Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(87 sites)
China
Affiliated Hospital of Hebei University, Baoding Beijing Cancer Hospital, Beijing Beijing Friendship Hospital, Capital Medical University, Beijing Beijing Tongren Hospital, Beijing Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing